Barclays lowered the firm’s price target on Tarsus Pharmaceuticals (TARS) to $60 from $62 and keeps an Overweight rating on the shares following the Q4 report. The firm says Xdemvy 2025 sales growth will vary by quarter.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals Reports Strong 2024 Financial Results
- Tarsus Pharmaceuticals price target lowered to $70 from $75 at BofA
- Tarsus Pharmaceuticals: Strong Buy Rating Driven by Impressive Financial Performance and Strategic Growth Positioning
- Tarsus Pharmaceuticals reports Q4 EPS (60c), consensus (82c)
- Strong Growth Prospects and Market Expansion Drive Buy Rating for Tarsus Pharmaceuticals